Blackstone and TPG in Advanced Talks to Acquire Hologic for Over $17 Billion

Source: Scientific Instrumentation Professional

Blackstone and TPG Close to Acquiring Hologic for Over $17 Billion.

According to informed sources,Blackstone Group and TPG Inc. have entered the advanced negotiation phase to acquire medical device manufacturer Hologic Inc., with the transaction valuation, including debt, potentially exceeding $17 billion (approximately 121.1 billion yuan).

Informed sources who requested anonymity said that the deal might be announced within the next few days, with the acquisition price currently under negotiation exceeding $75 per share. Following Bloomberg's report on the talks, Hologic's shares rose about 6% in after-hours trading and closed up 2% at $69.85 in New York on Friday, corresponding to a market value of over $15.5 billion.

In May this year, two private equity firms offered an acquisition bid of approximately $16 billion (including debt), or $70-72 per share, but were rejected by Hologic. Its current stock price has fallen to around $66, corresponding to a market value of approximately $14.7 billion.

HOLOGIC (Gen-Probe), founded in 1985, is headquartered in Boston, Massachusetts, USA. The company's main businesses are medical, diagnostic, and providing comprehensive solutions for women's health. Representative products include the Selenia Dimensions digital mammography system and the NovaSure® impedance-controlled endometrial ablation system.

Hologic is a world leader in technology for women's health services, including: breast cancer diagnosis and treatment, cervical cancer screening, prenatal testing, and osteoporosis detection. HOLOGIC is divided into four business units: Diagnostics, Breast Health, Gynecological Surgery, and Skeletal Health. The company holds a leading position in HPV testing, ranking among the top three alongside well-known companies Roche and Qiagen.

HOLOGICGen-Probe is committed to the development, manufacturing, and sales of rapid, accurate, and efficient molecular diagnostic products and services globally. Its products focus on disease diagnosis, blood screening, and ensuring transplant compatibility, aiming to improve early diagnosis and minimally invasive treatment through early testing and screening, saving lives in a timely manner.

HOLOGIC Gen-Probe Molecular Diagnostic Technology is a globally leading technology. On one hand, it features advanced RNA technology and has made remarkable achievements in the molecular diagnostics fields of women's health, prostate oncology, virology, blood screening, infectious diseases, and genetic disorders. Its core products include the APTIMA reagents, which can be used to test for chlamydia and gonorrhea, the two most common bacterial sexually transmitted diseases (STDs), as well as trichomonas vaginalis and other parasitic infectious diseases. It can also be used to test for human papillomavirus (HPV), the main cause of cervical cancer. Meanwhile, HOLOGIC Gen-Probe continues to develop new types of reagents to meet the testing needs of clinical laboratories. On the other hand, the fully automated, closed, integrated platform—the PANTHER system—has received approval from the U.S. FDA. It can continuously load various new testing items, providing more safe and rapid detection with both specificity and sensitivity exceeding 90%, far surpassing general testing methods in accuracy. Based on the aforementioned core technologies, HOLOGIC Gen-Probe can provide unique molecular diagnostic solutions for clinical laboratories.